GlaxoSmithKline Ties Up Loose Ends With Relovair –

GlaxoSmithKline Ties Up Loose Ends With Relovair
The FDA recently made more stringent requirements for drugs that contain long-acting beta agonists for the treatment of asthma due to safety concerns.
Glaxo, Theravance report Relovair safety dataBusinessWeek
GlaxoSmithKline, Theravance Combined Drug for COPD Shows Postitive ResultsFOXBusiness
GSK and Theravance announce combination ICS/LABA Phase II results in the MarketWatch (press release)
Proactive Investors USA & Canada –FierceBiotech –RTT News
all 39 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.